Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

Breast cancer research : BCR - 1 Jan 2010

Gor Priya P, Su H Irene, Gray Robert J, Gimotty Phyllis A, Horn Michelle, Aplenc Richard, Vaughan William P, Tallman Martin S, Rebbeck Timothy R, DeMichele Angela

Abstract excerpt

INTRODUCTION: Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible mechanism of treatment failure. We hypothesize that functional single nucleotide polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Doxorubicin

Share to Fluorouracil

Share to Lymph Nodes

Share to Lymphatic Metastasis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 20459744
DOI: 10.1186/bcr2570
PMCID: PMC2917014

Genes

GSTM1
GSTP1
GSTT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.PMID 20459744Read ↗

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.Semantic proximity Read ↗

Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.Semantic proximity Read ↗

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerSemantic proximity Read ↗

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.Semantic proximity Read ↗

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Semantic proximity Read ↗

Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.Semantic proximity Read ↗

Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Semantic proximity Read ↗

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.